These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21641692)

  • 1. Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.
    Chang JS; El-Gamal MI; Lee WS; Anbar HS; Chung HJ; Kim HI; Cho YJ; Lee BS; Lee SA; Moon JY; Lee DJ; Jeon HR; Lee J; Choi YW; Oh CH
    Eur J Med Chem; 2011 Sep; 46(9):3564-9. PubMed ID: 21641692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
    El-Gamal MI; Anbar HS; Chung HJ; Kim HI; Cho YJ; Lee BS; Lee SA; Moon JY; Lee DJ; Kwon D; Choi WJ; Jeon HR; Oh CH
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1347-50. PubMed ID: 23347686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.
    Park JH; Chang JS; El-Gamal MI; Choi WK; Lee WS; Chung HJ; Kim HI; Cho YJ; Lee BS; Jeon HR; Lee YS; Choi YW; Lee J; Oh CH
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5895-9. PubMed ID: 20728357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.
    Liu D; Hu P; Matsushima N; Li X; Li L; Jiang J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):190-7. PubMed ID: 17602900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations.
    Jiang J; Liu D; Hu P
    Pharmazie; 2009 May; 64(5):323-6. PubMed ID: 19530443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
    He L; Wickremasingha P; Lee J; Tao B; Mendell-Harary J; Walker J; Wight D
    J Clin Pharmacol; 2014 Jan; 54(1):61-9. PubMed ID: 24019110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A novel synthesis of olmesartan medoxomil and examination of its related impurities].
    Wu TZ; Liu XH; Zhang FL; Xie MH
    Yao Xue Xue Bao; 2006 Jun; 41(6):537-43. PubMed ID: 16927829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.
    Ishizuka T; Fujimori I; Kato M; Noji-Sakikawa C; Saito M; Yoshigae Y; Kubota K; Kurihara A; Izumi T; Ikeda T; Okazaki O
    J Biol Chem; 2010 Apr; 285(16):11892-902. PubMed ID: 20177059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application.
    Sengupta P; Sarkar AK; Bhaumik U; Chatterjee B; Roy B; Chakraborty US; Pal TK
    Biomed Chromatogr; 2010 Dec; 24(12):1342-9. PubMed ID: 21077253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
    Yoshihara K; Gao Y; Shiga H; Wada DR; Hisaoka M
    Clin Pharmacokinet; 2005; 44(12):1329-42. PubMed ID: 16372830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects.
    Bolbrinker J; Huber M; Scholze J; Kreutz R
    Fundam Clin Pharmacol; 2009 Dec; 23(6):767-74. PubMed ID: 19659504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174.
    Yan YD; Kim HK; Seo KH; Lee WS; Lee GS; Woo JS; Yong CS; Choi HG
    Mol Pharm; 2010 Dec; 7(6):2132-40. PubMed ID: 20849146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.
    Kang MJ; Kim HS; Jeon HS; Park JH; Lee BS; Ahn BK; Moon KY; Choi YW
    Drug Dev Ind Pharm; 2012 May; 38(5):587-96. PubMed ID: 21988221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects.
    Kreutz R; Bolbrinker J; Huber M
    Clin Drug Investig; 2006; 26(1):29-34. PubMed ID: 17163232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics.
    Tanaka H; Nagasawa Y; Matsui I; Hamano T; Iwatani H; Kawada N; Horio M; Ito T; Isaka Y; Imai E
    Clin Exp Nephrol; 2009 Feb; 13(1):61-5. PubMed ID: 18574553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability.
    Lee BS; Kang MJ; Choi WS; Choi YB; Kim HS; Lee SK; Lee J; Choi YW
    Arch Pharm Res; 2009 Nov; 32(11):1629-35. PubMed ID: 20091278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.
    Kodati D; Kotakonda HK; Yellu N
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):573-581. PubMed ID: 27535556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.
    Chrysant SG; Dimas B; Shiraz M
    J Hum Hypertens; 2007 Sep; 21(9):699-708. PubMed ID: 17554345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
    Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biliary excretion of olmesartan, an anigotensin II receptor antagonist, in the rat.
    Takayanagi M; Sano N; Takikawa H
    J Gastroenterol Hepatol; 2005 May; 20(5):784-8. PubMed ID: 15853995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.